Michelle Gomes

Dr. Michelle Gomes

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2008 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
ZXZhen Xu
Zhen Xu
RPRichard C Page
Richard C Page
MGMichelle Gomes
Michelle Gomes
EKEkta Kohli
Ekta Kohli
JNJay C Nix
Jay C Nix
SMSaurav Misra
Saurav Misra

1 October 2008 in Biochemistry
Verified
Journal Article
Closed access
MGMichelle Gomes
Michelle Gomes
SWStephanie B. Wall
Stephanie B. Wall
KTKazuo Takahashi
Kazuo Takahashi
JNJan Novak
Jan Novak
MRMatthew B. Renfrow
Matthew B. Renfrow
AHAndrew B. Herr
Andrew B. Herr

1 April 2016 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
AHAnn J. Hessell
Ann J. Hessell
DMDelphine C. Malherbe
Delphine C. Malherbe
FPFranco Pissani
Franco Pissani
SMSean McBurney
Sean McBurney
SKShelly J. Krebs
Shelly J. Krebs
NHNancy L. Haigwood
Nancy L. Haigwood
Advancement in immunogen selection and vaccine design that will rapidly elicit a protective Ab response is considered critical for HIV vaccine protective efficacy. Vaccine-elicited Ab responses must therefore have the capacity to prevent infection by neutralization-resistant phenotypes of transmitted/founder (T/F) viruses that establish infection in humans. Most vaccine candidates to date have been ineffective at generating Abs that neutralize T/F or early variants. In this study, we report that coimmunizing rhesus macaques with HIV-1 gp160 DNA and gp140 trimeric protein selected from native envelope gene sequences (envs) induced neutralizing Abs against Tier 2 autologous viruses expressing cognate envelope (Env). The Env immunogens were selected from envs emerging during the earliest stages of neutralization breadth developing within the first 2 years of infection in two clade B–infected human subjects. Moreover, the IgG responses in macaques emulated the targeting to specific regions of Env known to be associated with autologous and heterologous neutralizing Abs developed within the human subjects. Furthermore, we measured increasing affinity of macaque polyclonal IgG responses over the course of the immunization regimen that correlated with Tier 1 neutralization. In addition, we report firm correlations between Tier 2 autologous neutralization and Tier 1 heterologous neutralization, as well as overall TZM-bl breadth scores. Additionally, the activation of Env-specific follicular helper CD4 T cells in lymphocytes isolated from inguinal lymph nodes of vaccinated macaques correlated with Tier 2 autologous neutralization. These results demonstrate the potential for native Env derived from subjects at the time of neutralization broadening as effective HIV vaccine elements.

30 March 2023 in Nature Chemistry
Verified
Journal Article
Closed access
PDF file
LWLei G Wang
Lei G Wang
AMAntonio R. Montaño
Antonio R. Montaño
JCJason R. Combs
Jason R. Combs
NMNathan P. McMahon
Nathan P. McMahon
ASAllison Solanki
Allison Solanki
SGSummer L Gibbs
Summer L Gibbs

16 December 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SKShelly J. Krebs
Shelly J. Krebs
SMSean P. McBurney
Sean P. McBurney
DKDina N. Kovarik
Dina N. Kovarik
CWChelsea D. Waddell
Chelsea D. Waddell
Juan JaworskiJuan Jaworski
Juan Jaworski
NHNancy L. Haigwood
Nancy L. Haigwood
Developing a vaccine that overcomes the diversity of HIV-1 is likely to require a strategy that directs antibody (Ab) responses toward conserved regions of the viral Envelope (Env). However, the generation of neutralizing Abs (NAbs) targeting these regions through vaccination has proven to be difficult. One conserved region of particular interest is the membrane proximal external region (MPER) of Env located within the gp41 ectodomain. In order to direct the immune response to this region, the MPER and gp41 ectodomain were expressed separately as N-terminal fusions to the E2 protein of Geobacillus stearothermophilus. The E2 protein acts as a scaffold by self-assembling into 60-mer particles, displaying up to 60 copies of the fused target on the surface. Rabbits were immunized with E2 particles displaying MPER and/or the gp41 ectodomain in conjunction with DNA encoding full-length gp160. Only vaccines including E2 particles displaying MPER elicited MPER-specific Ab responses. NAbs were elicited after two immunizations that largely targeted the V3 loop. To overcome V3 immunodominance in the DNA component, E2 particles displaying MPER were used in conjunction with gp160 DNA lacking hypervariable regions V2, V3, or combined V1V2V3. All rabbits had HIV binding Ab responses and NAbs following the second vaccination. Using HIV-2/HIV-1 MPER chimeric viruses as targets, NAbs were detected in 12/16 rabbits after three immunizations. Low levels of NAbs specific for Tier 1 and 2 viruses were observed in all groups. This study provides evidence that co-immunizing E2 particles displaying MPER and gp160 DNA can focus Ab responses toward conserved regions of Env.

30 April 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
EPEmily J. Platt
Emily J. Platt
MGMichelle Gomes
Michelle Gomes
DKDavid Kabat
David Kabat
Despite structural knowledge of broadly neutralizing monoclonal antibodies (NMAbs) complexed to HIV-1 gp120 and gp41 envelope glycoproteins, virus inactivation mechanisms have been difficult to prove, in part because neutralization assays are complex and were previously not understood. Concordant with recent evidence that HIV-1 titers are determined by a race between entry of cell-attached virions and competing inactivation processes, we show that NMAb 2G12, which binds to gp120 N-glycans with α (1, 2)-linked mannose termini and inhibits replication after passive transfer into patients, neutralizes by slowing entry of adsorbed virions. Accordingly, apparent neutralization is attenuated when a kinetically competing virus inactivation pathway is blocked. Moreover, removing 2G12 from media causes its dissociation from virions coupled to accelerated entry and restored infectivity, demonstrating the reversibility of neutralization. A difference between 2G12 dissociation and infectivity recovery rates implies that the inhibited complexes at virus–cell junctions contain several 2G12’s that must dissociate before entry commences. Quantitative microscopy of 2G12 binding and dissociation from single virions and studies using a split CCR5 coreceptor suggest that 2G12 competitively inhibits interactions between gp120’s V3 loop and the tyrosine sulfate-containing CCR5 amino terminus, thereby reducing assembly of complexes that catalyze entry. These results reveal a unique reversible kinetic mechanism for neutralization by an antibody that binds near a critical V3 region in the glycan shield of gp120.